Browse > Article

Fluoroquinolone Resistance and gyrA and parC Mutations of Escherichia coli Isolated from Chicken  

Lee Young-Ju (College of Veterinary Medicine, Kyungpook National University)
Cho Jae-Keun (Daegu Metropolitan City Research Institute of Health & Environment)
Kim Ki-Seuk (College of Veterinary Medicine, Kyungpook National University)
Tak Ryun-Bin (College of Veterinary Medicine, Kyungpook National University)
Kim Ae-Ran (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry)
Kim Jong-Wan (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry)
Im Suk-Kyoung (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry)
Kim Byoung-Han (National Veterinary Research and Quarantine Service, Ministry of Agriculture & Forestry)
Publication Information
Journal of Microbiology / v.43, no.5, 2005 , pp. 391-397 More about this Journal
Abstract
Escherichia coli is a common inhabitant of the intestinal tracts of animals and humans. The intestines of animals also represent an ideal environment for the selection and transfer of antimicrobial resistance genes. The aim of this study was to investigate the resistance of E. coli isolated from chicken fecal samples to fluoroquinolones and to analyze the characterization of mutations in its gyrA and parC gene related resistance. One hundred and twenty-eight E. coil isolates showed a high resistance to ciprofloxacin (CIP; $60.2\%$), enrofloxacin (ENO; $73.4\%$) and norfloxacin (NOR; $60.2\%$). Missense mutation in gyrA was only found in the amino acid codons of Ser-83 or Asp-87. A high percentage of isolates ($60.2\%$) showed mutations at both amino acid codons. Missense mutation in parC was found in the amino acid codon of Ser-80 or Glu-84, and seven isolates showed mutations at both amino acid codons. Isolates with a single mutation in gyrA showed minimal inhibitory concentrations (MIC) for CIP (${\le}0.5\;to\;0.75{\mu}g/ml$), ENO (1 to $4{\mu}g/ml$) and NOR (0.75 to $4{\mu}g/ml$). These MIC were level compared to isolates with two mutations, one in gyrA and one in parC, and three mutations, one in gyrA and two in parC (CIP, ${\le}0.5\;to\;3{\mu}g/ml;\;ENO,\;2\;to\;32<{\mu}g/ml;\;NOR,\;1.5\;to\;6\;{\mu}g/ml$). However, the isolates with two mutation in gyrA regardless of whether there was a mutation in parC showed high MIC for the three fluoroquinolones (CIP, 0.75 to $32{\le}{\mu}g/ml;\;ENO,\;3\;to\;32{\le}{\mu}g/ml;\;NOR,\;3\;to\;32{\le}{\mu}g/ml$). Interestingly, although the E. coil used in this study was isolated from normal flora of chicken, not clinical specimens, a high percentage of isolates showed resistance to fluoroquinolones and possessed mutations at gyrA and parC associated with fluoroquinolone resistance.
Keywords
E. coli; fluoroquinolone resistance; gyrA gene; parC gene;
Citations & Related Records

Times Cited By Web Of Science : 15  (Related Records In Web of Science)
Times Cited By SCOPUS : 15
연도 인용수 순위
1 Bass, L., C.A. Liebert, M.D. Lee, A.O. Summers, D.G. White, S.G. Thayer, and J.J. Maurer. 1999. Incidence and characterization of integrons, genetic elements mediating multiple-drug resistance, in avian Escherichia coli. Antimicrob. Agents Chemother. 43, 2925-2929   PUBMED
2 Everett, M.J., Y.F. Jin, V. Ricci, and L.J. Piddock. 1996. Contribution of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40, 2380-2386   PUBMED
3 Heisig, P., H. Schedletzdy, and H. Falkenstein-Paul. 1993. Mutations in the gyrA gene of a high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 37, 696-701   DOI   PUBMED   ScienceOn
4 Kato, J., H. Suzuki, and H. Ikeda. 1992. Purification and characterization of DNA topoisomerase IV in Eshcherichia coli. J. Biol. Chem. 267, 25676-25684   PUBMED
5 NCCLS. 2000. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard-fifth edition. M31-A
6 Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34, 1271-1272   DOI   PUBMED   ScienceOn
7 Blanche, F., B. Cameron, F.X. Bernard, L. Maton, B. Manse, L., Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40, 2714-2720   PUBMED
8 Cambau, F. and L. Gutmann. 1993. Mechanisms of resistance to quionolones. Drugs 45, 15-23   PUBMED
9 Aarestrup, F.M., Y. Agerso, P. Gerner-Smidt, M. Madsen, and L.B. Jensen. 2000. Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis and Enterococcus faecium from humans in the community, broilers, and pigs in Denmark. Diagn. Microbiol. Infect. Dis. 37, 127-37   DOI   ScienceOn
10 Oram, M. and L.M. Fisher. 1991. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob. Agents Chemother. 35, 387-389   DOI   PUBMED   ScienceOn
11 Amara, A., Z. Ziani, and K. Bouzoubaa. 1995. Antibiotic resistance of Escherichia coli strains isolated in Morocco from chickens with colibacillosis. Vet. Microbiol. 43, 325-330   DOI   ScienceOn
12 Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40, 879-885   PUBMED
13 Soussy, C.J., J.S. Wolfson, E.Y. Ng, and D.C. Hooper. 1993. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob. Agents Chemother. 37, 2588-2592   DOI   PUBMED   ScienceOn
14 Prescott, J.F. and Baggot, J.D. 1993. Fluoroquinolones. p. 252-262. In Antimicrobial therapy in veterinary medicine, 2nd ed, Iowa State University Press, Ames, Iowa
15 Hooper, D.C. 1995. Quinolone mode of action. Drugs. 49(Suppl. 2), 10-15   DOI   ScienceOn
16 Han, H.S., H.Y. Nam, Y.J. Koh, J.S. Hur, and J.S. Jung. 2003. Molecular bases of high-level streptomycin resistance in Pseudomonas marginalis and Pseudomonas syringae pv. actinidiae. J. Microbiol. 41, 16-21
17 Lagatolla, C., L. Dolzani, E. Tonin, A. Lavenia, M.D. Michele, T. Tommasini, and C. Monti-Bragadin. 1996. PCR ribotyping for characterizing Salmonella isolates of different serotypes. J. Clin. Microbiol. 34, 2440-2443   PUBMED
18 Lee, Y.J., K.S. Kim, J.H. Kim, and R.B. Tak. 2004. Salmonella gallinarum gyrA mutations associated with fluoroquinolone resistance. Avian Pathol. 33, 251-257   DOI   ScienceOn
19 Peng, H. and K. Marians. 1993. Escherichia coli topoisomerase IV: purification, characterization, subunit structure, and subunit interactions. J. Biol. Chem. 268, 24481-24490
20 Quabdesselam, S., D.C. Hopper, J. Tankovic, and C.J. Soussy. 1995. Detection of gyrA and gyrB mutations in quinoloneresistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob. Agents Chemother. 39, 1667-1670   DOI   PUBMED   ScienceOn
21 Hoshino, K., A. Kitamura, I. Morrissey, K. Sato, J. Kato, and H. Ikeda. 1994. Inhibition of quinolones against topoisomerase IV from Escherichia coli and comparison with the inhibitory potency against DNA gyrase. Antimicrob. Agents Chemother. 38, 2623-2627   DOI   PUBMED   ScienceOn
22 Pinheiro, E.T., B.P.F.A. Gomes, D.B. Drucker, A.A. Zaia, C.C.R. Ferraz, and F.J. Souza-Filho. 2004. Antimicrobial susceptibility of Enterococcus faecalis isolated from canals of root filled teeth with periapical lesions. Int. Endo. J. 37, 756-763   DOI   ScienceOn
23 Kumagai, Y., J.I. Kato, K. Hoshino, T. Akasaka, K. Sato, and H. Ikeda. 1996. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob. Agents Chemother. 40, 710-714   PUBMED
24 Chin, S.C., N. Abdullah, T.W. Siang, and H.Y. Wan. 2005. Plasmid profiling and curing of Lactobacillus strains isolated from the gastrointestinal tract of chicken. J. Microbiol 43, 251-256
25 Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13, 641-653   DOI   ScienceOn
26 Bonten, M., E. Stobberingh, J. Philips, and A. Houben. 1990. High prevalence of antibiotic resistant Escherichia coli in faecal samples of students in the south-east of The Netherlands. J. Antimicrob. Chemother. 26, 585-592   DOI
27 Han, M.W. and T.H. Wood. 1969. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J. Bacteriol. 99, 238-24   PUBMED
28 Khodursky, A.B. and Cozzarelli, N.R. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 274, 27668-27677
29 Murray, B.E. 1990. The life and times of the Enterococcus. Clin. Microbiol. Rev. 3, 46-65   PUBMED
30 Lee, Y.J., K.S. Kim, Y.K. Kwon, and R.B. Tak. 2003. Biochemical characteristics and antimicrobials susceptibility of Salmonella gallinarum isolated in Korea. J. Vet. Sci. 4, 161-166